Summary
• Clearmind Medicine Inc. (CMND) shares rose 9% in after-hours trading to $0.1744 after a clinical trial update.
• Patient enrollment has begun at Tel Aviv Medical Center for a Phase I/IIa trial of CMND-100 targeting Alcohol Use Disorder.
• The Data and Safety Monitoring Board approved the trial’s continuation, indicating positive interim safety reviews and enhanced investor interest.
Clearmind Medicine Inc. (CMND) has increased by 9% in after-hours trading to a price of $0.1744, following its previous close of $0.16. This notable rise occurred amid routine trading conditions, as no fresh catalyst was evident beyond recent developments.
Enrollment Kicks Off at Tel Aviv Medical Center
The company recently announced the commencement of patient enrollment at Tel Aviv Sourasky Medical Center for its Phase I/IIa clinical trial of CMND-100 focused on Alcohol Use Disorder (AUD). The trial’s first patient has been successfully recruited, which contributes to the overall acceleration of the global study of this non-hallucinogenic neuroplastogen-derived therapeutic. This pivotal milestone aims to further advance Clearmind’s objectives in addressing major health issues.
Notably, as of November 25, 2025, the FDA-approved trial is gaining momentum with the Tel Aviv center joining a list of premier global medical sites, enhancing Clearmind’s credibility and visibility within the clinical research community.
Recent Developments and Clinical Trial Progress
Earlier this week, the Data and Safety Monitoring Board unanimously approved the continuation of the Phase I/IIa trial after a positive interim safety review. These developments coincide with the recruitment of the first patient at Tel Aviv, indicating the company’s accelerating progress in clinical research activities.
Clearmind has activated five leading global medical centers in its initiative, which includes prestigious institutions such as Yale and Johns Hopkins, demonstrating a strong collaborative network in clinical evaluation.
Market and Technical Picture
The stock is currently operating with an average volume of approximately 25.7 million over the past ten days, significantly above the three-month average volume of about 9 million. This spike in trading activity may suggest heightened investor interest as developments continue to unfold in Clearmind’s clinical trial endeavors.
From a technical standpoint, the company’s SMA indicators point to substantial recent underperformance, with deviations from key moving averages reflecting investor caution. Recent metrics show the stock’s RSI at 15.09, indicating it is in an oversold condition, which could influence trading dynamics moving forward.
Conclusion on Price Action Dynamics
With shares reacting positively to the latest updates regarding its clinical trials, investors seem to be focusing on the strategic advancements made by Clearmind. The ongoing recruitment of patients and favorable reviews from safety monitoring bodies reflect cemented confidence in the company’s research pathway, highlighting how such developments may foster increased interest as market dynamics continue.